The long-term effect of oral isotretinoin therapy on macula ganglion cell complex thickness

Abstract

Purpose: To evaluate the long-term effect of oral isotretinoin therapy on macula ganglion cell complex (GCC) thickness by spectral domain optical coherence tomography (SD-OCT).

Materials and methods: Newly diagnosed cystic acne patients who received low dose for a long time systemic isotretinoin therapy were included in this study. Thorough ophthalmic evaluation and GCC thickness analysis by using SD-OCT were performed at baseline, and at 1, 3, 6, and 12 months of treatment.

Results: Forty-eight eyes of 24 patients (15 females, 9 males) were included in the study. The mean age of patients was 19.37 ± 2.74 years (range 14–25 years). The full ophthalmologic examination was normal in all eyes before treatment. During the treatment there were no change in visual acuity, refractive error, intraocular pressure and tear break-up time. The mean GCC thicknesses were 81.45 ± 4.91, 81.45 ± 5.12, 81.81 ± 4.68, 81.87 ± 4.91 and 81.64 ± 5.09 μm at pretreatment and at 1, 3, 6, and 12 months of treatment, respectively (p = 0.803).

Conclusion: One-year systemic use of isotretinoin had no significant effect on the thickness of macula ganglion cell. Macular ganglion cell analysis is useful for determining and following the toxic effects of systemic drugs on the retina. However, it is more rational to consider it as an adjunct to electrophysiological testing rather than used alone.

Keywords:

• Ganglion cell complex layer
• optical coherence tomography
• systemic isotretinoin therapy
• retinal toxicity
• macular ganglion cell analysis

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.